Orthocell (ASX:OCC) has seen its share price jump on Thursday as the company unveils its latest early-stage successes observed in Australian prostate surgery patients who use nerve repair product Remplir.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This isn’t the first time Orthocell has flagged that its Remplir product has applications in prostate surgery, but the company did report Thursday that 100 prostate surgeries using the nerve healing product have now been performed “with multiple surgeons nationwide” now familiar with the product.
This, Orthocell states, is a “commercial opportunity.”
Further investments into research will be conducted as the company continues to pivot to the U.S., to which end the company has also established an advisory committee of sorts to help smooth out the process.
Then there’s the company eyeing a US$2 billion addressable market, though addressable markets are pretty broad in nature, kind of like exploration targets.
Still, prostate surgery remains a key focus as the density of nerves in the area – we’re talking areas proximate to the sex organs, after all – still poses complications for patients post-op, even despite advancements in robotic technology. That means that for many prostate surgery patients, erectile dysfunction can often follow. (Another fun fact: Prostate tests no longer involve a doctor’s finger.)
“We’re thrilled to see Remplir being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair,” Orthocell CEO Paul Anderson said.
“This demonstrates the utility of the product and represents the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.”
OCC last traded at $1.07/sh.
Join the discussion: See what HotCopper users are saying about Orthocell Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.